Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes

Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes

Abstract Background According to the 2018 NIA-AA research framework, Alzheimer’s disease (AD) is not defined by the clinical consequences of the disease, but by its underlying pathology, measured by biomarkers. Evidence of both amyloid-β (Aβ) and phosphorylated tau protein (p-tau) deposition—assesse...

Full description

Bibliographic Details
Main Authors: Tiziana Carandini, Andrea Arighi, Luca Sacchi, Giorgio G. Fumagalli, Anna M. Pietroboni, Laura Ghezzi, Annalisa Colombi, Marta Scarioni, Chiara Fenoglio, Milena A. De Riz, Giorgio Marotta, Elio Scarpini, Daniela Galimberti
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Dementia
CSF
Clinical neurology
Biomarkers
PET
Online Access:http://link.springer.com/article/10.1186/s13195-019-0543-7

Internet

http://link.springer.com/article/10.1186/s13195-019-0543-7

Similar Items